Advertisement

Blockage of HOTAIR Reduced Cell Proliferation in Human Ovarian Cancer Cells Through Upregulation of AKT2

  • Mahsa Sabet
  • Mohammadreza SharifiEmail author
  • Mansour Heidari
  • Mohammad Kazemi
  • Nahid Babaei
Original Article
  • 45 Downloads

Abstract

Purpose

Ovarian cancer (OC) is the most leading cause of cancer-related death in women. lncRNA HOTAIR is emerging as an onco-lncRNA that its overexpression provokes progression and metastasis in OC. In this study, we focused on evaluating the efficiency of antisense-based HOTAIR inhibition in OC tumor cells death.

Methods

We transfected antisense LNA GapmeR into OC cell line (SKOV3). Then, the survival rates of SKOV3 were measured by MTT at all three time points after transfection. Moreover, we examined the expression level of AKT2 in SKOV3 under the influence of GapmeRs using qPCR at 24, 48 and 72 h after transfection.

Results

The viability of SKOV3 was significantly reduced over time under the suppression of lncRNA HOTAIR. The qPCR results disclosed the remarkable increase in AKT2 expression level via inhibition of HOTAIR in SKOV3 cell line.

Conclusion

Our data imply that inhibition of HOTAIR by antisense LNA GapmeR induced OC cell death. Hence, we concluded that antisense-based strategies might be considered as a potential therapeutic approach in OC treatment.

Keywords

Ovarian cancer Long non-coding RNA lncRNA HOTAIR Cell death 

Notes

Acknowledgements

This study was conducted with the support of Isfahan University of Medical Science Bushehr Branch, Islamic Azad University (Iran).

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefGoogle Scholar
  2. 2.
    Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN, et al. Pathology and classification of ovarian tumors. Cancer Interdiscip Int J Am Cancer Soc. 2003;97(S10):2631–42.Google Scholar
  3. 3.
    Salani R, Backes FJ, Fung MFK, Holschneider CH, Parker LP, Bristow RE, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204(6):466–78.CrossRefGoogle Scholar
  4. 4.
    Mutch DG, editor. Surgical management of ovarian cancer. Seminars in oncology. Amsterdam: Elsevier; 2002.Google Scholar
  5. 5.
    Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3(7):502.CrossRefGoogle Scholar
  6. 6.
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51(1):15–36.CrossRefGoogle Scholar
  7. 7.
    Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol. 2001;81(3):380–90.CrossRefGoogle Scholar
  8. 8.
    Ono K, Tanaka T, Tsunoda T, Kitahara O, Kihara C, Okamoto A, et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res. 2000;60(18):5007–11.PubMedGoogle Scholar
  9. 9.
    Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155.CrossRefGoogle Scholar
  10. 10.
    Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10(1):38.CrossRefGoogle Scholar
  11. 11.
    Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao H, et al. Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer. Oncotarget. 2016;7(22):32433.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Zhong Y, Gao D, He S, Shuai C, Peng S. Dysregulated expression of long noncoding RNAs in ovarian cancer. Int J Gynecol Cancer. 2016;26(9):1564–70.CrossRefGoogle Scholar
  13. 13.
    Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071.CrossRefGoogle Scholar
  14. 14.
    Yang Z, Zhou L, Wu L-M, Lai M-C, Xie H-Y, Zhang F, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol. 2011;18(5):1243–50.CrossRefGoogle Scholar
  15. 15.
    Yiwei T, Hua H, Hui G, Mao M, Xiang L. HOTAIR interacting with MAPK1 regulates ovarian cancer skov3 cell proliferation, migration, and invasion. Med Sci Monit Int Med J Exp Clin Res. 2015;21:1856.Google Scholar
  16. 16.
    Qiu J, Wang Y, Ding J, Jin H, Yang G, Hua K. The long non-coding RNA HOTAIR promotes the proliferation of serous ovarian cancer cells through the regulation of cell cycle arrest and apoptosis. Exp Cell Res. 2015;333(2):238–48.CrossRefGoogle Scholar
  17. 17.
    Osaki M, Oshimura M, Ito H. PI3 K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004;9(6):667–76.CrossRefGoogle Scholar
  18. 18.
    Gao N, Flynn DC, Zhang Z, Zhong X-S, Walker V, Liu KJ, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3 K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 2004;287(2):C281–91.CrossRefGoogle Scholar
  19. 19.
    Salehi M, Sharifi M. Induction of apoptosis and necrosis in human acute erythroleukemia cells by inhibition of long non-coding RNA PVT1. Mol Biol Res Commun. 2018;7(2):89.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88.CrossRefGoogle Scholar
  21. 21.
    Zhou X, Chen J, Tang W. The molecular mechanism of HOTAIR in tumorigenesis, metastasis, and drug resistance. Acta Biochim Biophys Sin. 2014;46(12):1011–5.CrossRefGoogle Scholar
  22. 22.
    Qiu J, Lin Y, Ye L, Ding J, Feng W, Jin H, et al. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. Gynecol Oncol. 2014;134(1):121–8.CrossRefGoogle Scholar
  23. 23.
    Slomovitz BM, Coleman RL. The PI3 K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012;18(21):5856–64.CrossRefGoogle Scholar
  24. 24.
    Li E, Zhao Z, Ma B, Zhang J. Long noncoding RNA HOTAIR promotes the proliferation and metastasis of osteosarcoma cells through the AKT/mTOR signaling pathway. Exp Ther Med. 2017;14(6):5321–8.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Cheng C, Qin Y, Zhi Q, Wang J, Qin C. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3 K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2018;107:2620–9.CrossRefGoogle Scholar
  26. 26.
    Yu Y, Lv F, Liang D, Yang Q, Zhang B, Lin H, et al. HOTAIR may regulate proliferation, apoptosis, migration and invasion of MCF-7 cells through regulating the P53/Akt/JNK signaling pathway. Biomed Pharmacother. 2017;90:555–61.CrossRefGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2019

Authors and Affiliations

  1. 1.Department of Cell Biology and Genetics, Bushehr BranchIslamic Azad UniversityBushehrIran
  2. 2.Department of Genetics and Molecular Biology, School of MedicineIsfahan University of Medical SciencesIsfahanIran
  3. 3.Department of Medical GeneticsTehran University of Medical SciencesTehranIran

Personalised recommendations